1644
#6

Attorney's Docket No. **G00694.70002.US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|---|---|---|
| Applicant | : | Richard S. Blumberg |
| Serial No. | : | 09/884,196 |
| Filed | : | June 19, 2001 |
| For | : | T CELL INHIBITORY RECEPTOR COMPOSITIONS AND USES THEREOF |
| Examiner | : | A. DeCloux |
| Art Unit | : | 1644 |
| Conf. No. | : | 5225 |



CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 10th day of October, 2002.

Monica E. Zombori

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

[X] Response to Restriction Requirement

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No fee is required. If a fee is determined to be required, the fee may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By: John R. Van Amsterdam

John R. Van Amsterdam, Reg No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. G00694.70002.US
Dated: October 10, 2002
**X10/10/02**

649982.1

Attorney's Docket No. **G00694.70002.US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



| | | |
|---|---|---|
| Applicant | : | Richard S. Blumberg |
| Serial No. | : | 09/884,196 |
| Filed | : | June 19, 2001 |
| For | : | T CELL INHIBITORY RECEPTOR COMPOSITIONS AND USES THEREOF |
| Examiner | : | A. DeCloux |
| Art Unit | : | 1644 |
| Conf. No. | : | 5225 |

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 10th day of October, 2002.

Monica E. Zombori

Commissioner for Patents
Washington, D.C. 20231

## RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This is responsive to the restriction requirement mailed on September 10, 2002. Applicants elect Group I, claims 10-12, 16-18 and 57-58, for prosecution with traverse.

### Remarks

Applicants traverse the restriction requirement on the basis that no additional burden would be placed on the Examiner to search and examine the claims in Groups III in addition to those in elected Group I.

The Examiner notes that the methods of Groups I and III are related in that they each require the use of an antibody as the agent that selectively cross-links biliary glycoprotein polypeptides, and that the endpoints of the methods are the same. The Examiner then states that differences between the methods of Groups I and III are that Group I methods are in vivo methods and Group III methods are in vitro methods. Applicants agree that this is the only